NCT00769483 2020-09-03
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
Clinical Trials
9 trialsNCT01605396 2019-03-25
MK-8669-064
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00635778 2018-10-09
MK-0646-002
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00759785 2018-08-15
MK-0646-013
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00925015 2018-08-15
Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00614393 2018-08-08
Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00694356 2018-08-08
Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00701103 2018-08-08
Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00610129 2015-11-20
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed